Ramamurty Changalvala

Ramamurty Changalvala has a diverse work experience in the pharmaceutical industry. Ramamurty began their career as a Process Chemist at Global bulk drugs, where they focused on scale-up, route selection, and process improvement for generic drug development. Ramamurty then moved on to work as a Postdoctoral Research Associate at the Natural Products and Glycotechnology Research Institute, where they developed methodologies and conducted research on anti-bacterial vaccines and oligosaccharides.

Afterwards, Ramamurty worked as a Research Scientist at CiVentiChem, supporting medicinal chemistry efforts for a pro-drug against Hepatitis C Virus. Ramamurty played a role in SAR, lead optimization, metabolite synthesis, and process development.

Next, they joined Chimerix, Inc. as a Research Scientist and later became a Senior Scientist. During this time, they were involved in the development of antiviral and anticancer drugs, managing different chemistry projects, and conducting literary research for patent and regulatory documents.

Ramamurty then worked at Novartis Institutes for BioMedical Research (NIBR), first as a Senior Research Advisor and later as an Associate Director. At NIBR, they made significant contributions to the development of oncology targets using radio ligand therapy and played a key role in advancing hit-to-lead projects. Ramamurty also designed and synthesized various cyclic/linear peptide-chelator conjugates for target validation and employed structure-based design for SAR studies.

Most recently, Ramamurty joined Curie Therapeutics as the Director of Chemistry, where they oversee chemistry-related activities.

From 2000 to 2006, Ramamurty Changalvala pursued a PhD in Organic chemistry at the Indian Institute of Chemical Technology.